Eli Lilly’s Muvalaplin Shows Heart Disease Promise

Eli Lilly announced positive Phase 2 results for muvalaplin, an investigational oral inhibitor targeting lipoprotein(a) [Lp(a)], a significant genetic risk factor for heart disease. The study showed muvalaplin reduced Lp(a) levels by up to 85.8% after 12 weeks, achieving its primary endpoint. Secondary endpoints, including reductions in apoB levels and Lp(a) thresholds, were also met.

This innovative oral approach offers a promising alternative to injectable therapies in development. Adverse events were comparable across treatment groups, and no deaths were reported. Further trials will explore its cardiovascular benefits.